Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and Pharmacokinetic (PK) profile of
JNJ-56021927 and its active metabolite JNJ-56142060 after single-dose administration of 60
milligram (mg), 120 mg, and 240 mg JNJ-56021927 as the tablet formulation in healthy male
Japanese participants.